Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial
Article Abstract:
Zidovudine in combination with low-dose lamivudine appears to be more effective and better tolerated than a higher dose combination therapy or when combined with zalcitabine as a treatment for patients with HIV infection. Two hundred fifty-four patients with HIV previously treated with zidovudine were randomly assigned to take zidovudine plus either zalcitabine, low-dose lamivudine, or high-dose lamivudine for 24 weeks or up to 52 weeks. Patients taking zidovudine plus low-dose lamivudine had the highest average increase in CD4 counts and reported the fewest side effects.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial
Article Abstract:
Stavudine appears to be effective in treating patients with HIV previously treated with zidovudine. Disease progress was monitored in 822 patients with HIV treated with either stavudine or continued zidovudine. All patients had previously taken zidovudine for at least six months. Patients taking stavudine had higher CD4+ counts, less nausea, and fewer signs of disease progression but more signs of neurological dysfunction that stopped when treatment was either stopped or reduced in strength. The risk for death was slightly lower in the group taking stavudine.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine
Article Abstract:
Doctors should consider switching an HIV patient to other AIDS drugs if the patient does not respond to indinavir, zidovudine, and lamivudine within eight weeks. The response should include an increase in CD4 T cell counts and a decrease in blood levels of the virus.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Efficacy of outpatient induction with low-dose intravaginal prostaglandin E2: a randomized, double-blind, placebo-controlled trial
- Abstracts: Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial
- Abstracts: Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine: implications for HIV screening
- Abstracts: Infection with hepatitis GB virus C in patients on maintenance hemodialysis. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis
- Abstracts: Sexual factors associated with cytomegalovirus seropositivity in human immunodeficiency virus-infected men. The use of auxiliary events to improve the analysis of survival for HIV-infected patients: application to the French Prospective Multicenter Cohort (SEROCO)